This summer, RegenLife raised 3 million euros from business angels and family offices to launch new R&D projects in neurology and prepare an industrial-scale device. Its technological approach using combined electromagnetic emissions is being tested at Montpellier University Hospital on 64 patients suffering from Alzheimer’s disease.
Innovating in the fight against Alzheimer’s disease by using multiple electromagnetic emissions. That’s the goal set by RegenLife: ” To date, no treatment is effective in preventing or treating Alzheimer’s disease,” explains Guillaume Blivet, the company’s president and co-founder. Rather than seeking to destroy the proteins that accumulate in the brain and cause the disease, we want to bring energy to the cells to fight neurodegeneration, with a non-invasive technology. ” This summer, RegenLife raised 3 million euros from business angels and family offices to launch new R&D projects in neurology at the end of the year and prepare an industrialized device. The latter are members of RegenLife Invest, an investment company dedicated exclusively to the start-up and chaired by RegenLife partner Jean-Michel Renck.
Tested at Montpellier University Hospital
The device developed by this innovative young company is currently being tested on 64 patients at Montpellier University Hospital. The principle: waves are emitted for several minutes a day over the skull and abdomen, from a helmet and breastplate. ” Half of the patients benefit from the actual technology, the other half from a placebo treatment,” says Guillaume Blivet. Started in September 2018, this clinical study will be completed during 2020. What sets RegenLife’s approach apart?” We are working on the principles of combined electromagnetic emissions, which do not exist in the field of neurology. We are targeting the brain-gut axis, potentially involved in Alzheimer’s disease. This dual application is unprecedented We’re always on the lookout for new ideas”, stresses the CEO, who began his career in public health. The company calls on physicists, microbiologists, neurologists and gastroenterologists, ” who collaborate with us on research projects or accompany us directly as scientific advisors “. Still in the seed stage and incubated at the Montpellier Business & Innovation Centre, RegenLife hopes to be on the market ” before 2022 “, with first sales in 2023.
Fund raising
RegenLife
Creation date: 2016
Chairman: Guillaume Blivet
Amount: 3 million euros
Employees: 12
Sector: medtech
